Q4 FY2026 · ended Jun 30, 2026 · Revenue $0, -100.0% YoY · Filed Aug 28, 2026
Ibio, Inc. (IBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q4 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $10.6 million. Free cash flow was -$6.2 million. As of Jun 30, 2026 it held $88.0 million in cash and investments and $2.2 million in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-10.60M
-105.3% vs year-ago quarter
Operating cash flow
$-6.23M
-35.0% vs year-ago quarter
Free cash flow
$-6.25M
-35.3% vs year-ago quarter
EPS
$-0.07
+79.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
64.31M
+227.2% vs year-ago quarter
Net cash
$85.84M
Q4 FY2026
Operating margin
-5951.0%
Q1 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IBIO (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1420720
- Former names
- iBio, Inc. (until Oct 19, 2026); iBioPharma, Inc. (until Aug 14, 2009); InB:Biotechnologies, Inc. (until Jul 17, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $100,000 | $200,000 |
| Operating income | -$11.4M | -$8.4M | -$9.4M | -$6.0M | -$5.2M |
| Net income | -$10.6M | -$7.7M | -$9.0M | -$5.7M | -$5.2M |
| Diluted EPS | -$0.07 | -$0.06 | -$0.09 | -$0.11 | -$0.36 |
| Operating cash flow | -$6.2M | -$6.1M | -$5.2M | -$5.7M | -$4.6M |
| Free cash flow | -$6.2M | -$6.1M | -$5.8M | -$5.7M | -$4.6M |
| Total assets | $99.1M | $85.8M | $64.4M | $64.2M | $23.2M |
| Total liabilities | $13.4M | $8.3M | $7.8M | $8.1M | $8.3M |
| Stockholders' equity | $85.7M | $77.5M | $56.6M | $56.0M | $14.9M |
| Cash and investments | $88.0M | $74.8M | $52.7M | $49.6M | $8.6M |
| Total debt | $2.2M | $2.3M | $2.5M | $2.6M | $2.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Oct 19, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| ARS | Annual report to shareholders | Sep 4, 2026 | Jun 30, 2026 |
| 10-K | Annual report | Aug 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 28, 2026 | Aug 28, 2026 |
All 909 Ibio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.